Chediak-Higashi syndrome: Complete engraftment after documented chimerism  by Ikeda, A.K. et al.
cord blood). Results: 13 patients have been enrolled: LCH (3), HLH
(2), Wiscott-Aldrich (1), mannosidosis (2), Krabbe’s (1), sickle cell (1),
thalassemia (2), and Kostmann’s (1). Median age  2.2 yearrs (0.4–
9.1). Stem cell sources were: MSD (3), unrelated UCB (3–5/6 HLA
matched, 1–6/6 HLA matched), 6/6 unrelated marrow (5), 6/6 unre-
lated PBSC (1). Thymoglobulin®toxicities were: (1) seizure course
completed and (1) grade IV hypotension (course aborted after two
doses). No other non-hematologic grades 3–4 toxicities were ob-
served. All patients achieved 	90% stable donor chimerism with no
primary or secondary graft failure. Median ANC recovery  15 days
(11–35). Three patients died of infections before day 100. One pateint
developed acute GVHD (grade 2 skin only) and limited chronic
GVHD (the patient with aborted Thymoglobulin® course). Ten
(77%) survived with median follow-up of 410 days (90–1030). Con-
clusions: This preparative regimen is very well tolerated with to date
no graft failure and stable donor chimerism even with cord blood.
Thymoglobulin®appears to provide good in vitro T-cell depletion
with minimal GVHD. Additional patients need to be enrolled to
verify these results.
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COMBINED HOME ENZYME REPLACEMENT THERAPY AND UNRELATED
CORD BLOOD TRANSPLANT FOR HURLER’S SYNDROME (MPSI)
Khimji, I.1, Lepage, C.1, Zalesky, L.2, Jimenez, P.2, Barbouth, D.3,
Elsas, L.3, Delgado, I.3, Briery, B.3, Gordon, P.3, Kleiner, G.I.3 1.
Jackson Memorial Hospital, Miami, FL; 2. Accredo Therapeutics, Fort
Lauderdale, FL; 3. University of Miami School of Medicine, Miami, FL.
Hurler’s syndrome is caused by mutations in the 
iduronidase
gene and results in progressive deterioration of the central nervous
system. Allogeneic bone marrow transplantation before the age of
2 years halts disease progression and prolongs life. Enzyme re-
placement therapy (ERT) reduces lysosomal storage of mucopo-
lysaccharides in the liver and ameliorates extracranial manifesta-
tions of disease. In most instances, ERT occurs in a day hospital
setting. Since enzyme replacement therapy can mitigate airway and
pulmonary manifestation of MPS I, we hypothesized that ERT in
the peri-transplant period (pre-HSCT and immediately post-
HSCT) would decrease transplant related complications. We per-
formed combined ERT and HSCT in a 12 month old boy with
MPSI. The patient received his ﬁrst dose of Aldurazyme at 5
months of age, shortly after MPSI diagnosis. He had received 16
infusions prior to referral to our center. Throughout his pre-
transplant workup, the patient received ERT at the local Trans-
plant House by a visiting nurse. There were no infusion related
toxicities. The patient received a 5/6 unrelated cord blood unit and
engrafted on day12. Hyperacute GVHD was treated successfully
with high dose methylprednisolone pulse. Following engraftment,
the child received 8 additional doses of Aldurazyme. One year
following transplant, he continues to have normal urine GAGs,
normal enzyme level, and continues to have developmental im-
provements. We conclude that in this case of combined outpatient
ERT infusion with HSCT, pre- and post-transplant ERT does not
interfere with engraftment or developmental improvements.
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BONE MARROW TRANSPLANTATION IN A CHILD WITH TYPE C OF
NIEMANN-PICK DISEASE (SECOND CASE IN THE WORLD)
Iravani, M.1, Nedaeifard, L.1, Alimoghaddam, K.1, Mousavi, A.1,
Karimi, M.1, Ghavamzadeh, A.1 1Hematology-Oncology and BMT
Research Center, Tehran University of Medical Sciences, Tehran, Islamic
Republic of Iran.
Niemann-Pick Disease Type C (NPC) is a lysosomal storage
disease caused by an error in cellular trafﬁcking of exogenous
cholesterol resulting in accumulation of unesteriﬁed cholesterol.
Hematopoietic stem cell transplantation for Niemann-Pick disease
is considered experimental, investigational, and unproven. We
report a 4-years 7 and months old girl with Niemann-Pick type C
disease who received an allogeneic BMT. Her disease presented
with prolonged neonatal icter, hepatosplenomegaly, failure to
thrive, and progressive neurodevelopmental delay from 2 years
ago. Bone marrow biopsy revealed abundant lipid-ﬁlled foamy
macrophages. Her serum sphingomyelinase assey was normal. She
received hematopoietic stem cells from a healthy HLA-identical
female sibling, 19 year old, donor. She had neutrophil recovery
(WBC0.5 109/L) at day 17 and platelet recovery (platelet	 20
109/L) at day 33 after transplantation. She had grade 1 skin
GVHD. She had no serious infection or complication and was
discharged after 38 days. Full engraftment was evidenced by re-
gression of the hepatosplenomegaly, markedly reduced foamy mac-
rophage inﬁltration in bone marrow, and STR-PCR of 90% (Short
Tandem Repeat-polymerase chain reaction) at day 30. She has not
had any serious problems except blood transfusion twice because of
anemia, since transplantation 3 months ago. Her donor has shown
symptoms of Multiple Sclerosis disease two months after trans-
plantation. Follow-up will show the long term effect of BMT on
her disease and neurocognitive development.
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CHEDIAK-HIGASHI SYNDROME: COMPLETE ENGRAFTMENT AFTER
DOCUMENTED CHIMERISM
Ikeda, A.K.1, Roberts, R.L.1, Campbell, K.J.1, Cheng, J.C.1,
Moore, T.B.1 1Mattel Children’s Hospital at UCLA, Los Angeles, CA.
We describe a 7 year old male with a history of Chediak-Higashi
syndrome who received a matched unrelated cord stem cell trans-
plantation in the accelerated phase and achieved complete donor
engraftment after initial partial chimerism. Chediak-Higashi syn-
drome is a rare autosomal disease characterized by partial oculo-
cutaneous albinism, recurrent bacterial infections, mild bleeding
diatheses, and both central and peripheral neuropathies. In late
childhood, these patients develop an accelerated phase character-
ized by pancytopenia, hepatosplenomegaly, and lymphocytic inﬁl-
trates. Death associated with the accelerated phase is secondary to
infection and hemorrhage. The diagnosis of Chediak-Higashi syn-
drome is made by microscopic visualization of the giant cytoplas-
mic granules in leukocytes or abnormal giant melanosomes in hair
shafts. Curative treatment entails bone marrow transplantation.
Hematopoietic chimeras have been documented with clinical im-
provement, particularly being free of the accelerated phase. Our
patient demonstrated chimerism at 30 days post-transplantation.
The DNA ﬁngerprinting analysis at this time showed 30% donor
and 70% recipient cells in the marrow. The neutrophils on the
peripheral blood smear, which contained large purplish inclusion
bodies, were far fewer than the number of normal neutrophils. At
day 77, the peripheral smear showed normal neutrophils and no
granulated leukocytes. Repeat bone marrow biopsy at 84 days
post-transplant showed complete engraftment; 90% donor mar-
row. Although hematopoietic chimerism may result in signiﬁcant
clinical improvement of patients with Chediak-Higashi, there may
be further self-selection for normal marrow cells over abnormal
cells even after the initial engraftment of bone marrow transplan-
tation.
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UNRELATED DONOR UMBILICAL CORD BLOOD TRANSPLANTATION IN
TWO CHILDREN WITH AMEGAKARYOCYTIC THROMBOCYTOPENIA
WITH RADIO-ULNAR SYNOSTOSIS
Staba, S.L.1, Sola, M.C.1, William, S.B.1 1University of Florida,
Gainesville, FL.
Congenital amegakaryocytic thrombocytopenia (CAMT) with
proximal radio-ulnar synostosis is a rare autosomal dominant dis-
order of thrombopoiesis and forearm abnormality. Four children
have previously been described in the literature, some with an
identiﬁed mutation of the HoxA11 gene. The fathers of the pre-
viously reported children had skeletal abnormalities, however nor-
mal platelet counts. We describe 2 children from the same family
who had radio-ulnar synostosis and CAMT and subsequently un-
derwent unrelated donor umbilical cord blood transplant (UCBT).
The mother has radio-ulnar synostosis without any hematologic
ﬁndings. Both children lack HOXA11 mutations and demonstrated
proximal radio-ulnar sysnostosis. The ﬁrst child had thrombocy-
topenia at birth, with a bone marrow initially showing normal
cellularity with signiﬁcantly decreased megakaryocytes. She pro-
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